Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 48.8%

Neg 48.8% Neu 0% Pos 0%

Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $42 to $40.